Protein Degradation and InhibitorsSignaling Pathways in DiseaseCAR-T cell therapy research

Yue Wei, Yunyun Gao, Ruijie Li, Yao Chen, Wenjing Bai, Peirui Zhao, Junchi Hu, Linfeng Li, Xing Wang, Guobing Yin, Yongjun Dang, Xiangqian Kong, Zufeng Guo

2026.2.1Acta Pharmaceutica Sinica B

DOI: 10.1016/j.apsb.2026.02.008

Abstract

Target-based drug screening typically relies on biochemical or affinity-based assays to identify compounds that modulate or bind to purified target proteins in vitro . However, additional cellular validation is essential to confirm genuine drug-target engagements. Integrating screening and validation within a single cellular assay could greatly expedite the drug discovery process. Herein, we developed a cellular ligand discovery method called CPSEA (cellular protein stability enhancement assay), which leverages the biophysical principle of ligand-induced stabilization of target proteins containing destabilizing mutations. Using CPSEA, we identified arteannuin B and colchicine as novel ligands for FKBP12 and KRAS G12S , respectively. Importantly, we introduced both experimental and computational strategies to identify destabilizing mutations, thereby broadening the applicability of CPSEA for target proteins with and without known stabilizing ligands. Overall, CPSEA represents a powerful cell-based screening strategy with significant potential in target-based drug discovery.

Citation format

WEI, Yue, et al. High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. Acta Pharmaceutica Sinica B, 2026, 16(7): 4524–4538.